StockNews.AI
CERT
StockNews.AI
167 days

Certara Appoints Dr. Adrian McKemey as President of Drug Development Solutions

1. Adrian McKemey appointed as President of Drug Development Solutions. 2. McKemey has over 25 years of R&D experience. 3. Leadership transition aims to enhance biosimulation and scientific services. 4. Certara focuses on improving drug development and accelerating therapies. 5. Company serves over 2,400 global biopharmaceutical and academic clients.

4m saved
Insight
Article

FAQ

Why Bullish?

The leadership change with an experienced figure may boost Certara's innovative capacity, similar to when key hires historically led to stock price increases.

How important is it?

The appointment is crucial for future strategic directions in drug development, aligning with investor interests.

Why Long Term?

Adrian McKemey's strategies may yield significant improvements over time, reminiscent of past strategic hires enhancing company performance.

Related Companies

IQVQTRXBCG
RADNOR, Pa., March 05, 2025 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in model-informed drug development, today announced the appointment of Adrian McKemey, Ph.D. as President of Drug Development Solutions, effective March 3rd, 2025. In this role, McKemey will lead Certara's global team of drug development scientists. Adrian joins Certara after serving as head of Enterprise Transformation at IQVIA and Senior Vice President and Head of the R&D Strategy Solutions at Quintiles. He has over 25 years of experience in research and development roles where he focused on business transformation, portfolio management and R&D strategies. Before IQVIA, he was a Principal with the Boston Consulting Group (BCG) working in the Life Sciences practice in New York. He holds a BSc (First Class) and a PhD in High Energy Nuclear Particle Physics from the University of London. The change is part of a planned leadership transition. Patrick Smith, PharmD. will continue to support Certara’s growth in science and innovation as Senior Vice President of Translational Sciences. Patrick and his leadership team successfully led and integrated the Certara services team building a unified offering of comprehensive scientific services for life sciences clients across the globe. “Adrian brings a mission-driven approach to improving drug development,” said William Feehery, Ph.D., Certara’s CEO. “His leadership will build upon recent accomplishments helping Certara further scale its biosimulation and scientific services to support the next generation of life-changing therapies.” “Certara’s leadership in biosimulation is key to de-risking the thorny issues I have seen the industry tackle for decades in clinical development. The rising adoption of in silico models into portfolio decision making can improve the probability of success at the asset and aggregate portfolio level,” said Adrian McKemey. “This role and the Certara portfolio present an ideal opportunity for me to positively impact the industry and accelerate medicines to patients.” About CertaraCertara accelerates medicines using biosimulation software, technology, and services to transform traditional drug discovery and development. Its clients include more than 2,400 biopharmaceutical companies, academic institutions, and regulatory agencies across 66 countries. Learn more at certara.com. Certara Contact:Sheila Rocchiosheila.rocchio@certara.com Media Contact:Alyssa Horowitzcertara@pancomm.com

Related News